These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. The effect of inhibitor binding on the structural stability and cooperativity of the HIV-1 protease. Todd MJ; Freire E Proteins; 1999 Aug; 36(2):147-56. PubMed ID: 10398363 [TBL] [Abstract][Full Text] [Related]
4. Inhibition of XMRV and HIV-1 proteases by pepstatin A and acetyl-pepstatin. Matúz K; Mótyán J; Li M; Wlodawer A; Tőzsér J FEBS J; 2012 Sep; 279(17):3276-86. PubMed ID: 22804908 [TBL] [Abstract][Full Text] [Related]
5. Impedance method for detecting HIV-1 protease and screening for its inhibitors using ferrocene-peptide conjugate/Au nanoparticle/single-walled carbon nanotube modified electrode. Mahmoud KA; Luong JH Anal Chem; 2008 Sep; 80(18):7056-62. PubMed ID: 18707132 [TBL] [Abstract][Full Text] [Related]
6. Purification of HIV-1 wild-type protease and characterization of proteolytically inactive HIV-1 protease mutants by pepstatin A affinity chromatography. Wondrak EM; Louis JM; Mora PT; Oroszlan S FEBS Lett; 1991 Mar; 280(2):347-50. PubMed ID: 2013336 [TBL] [Abstract][Full Text] [Related]
7. Effect of pH and nonphysiological salt concentrations on human immunodeficiency virus-1 protease dimerization. Tyagi SC; Simon SR; Carter CA Biochem Cell Biol; 1994; 72(5-6):175-81. PubMed ID: 7840936 [TBL] [Abstract][Full Text] [Related]
8. Substrate analogue inhibition and active site titration of purified recombinant HIV-1 protease. Tomasselli AG; Olsen MK; Hui JO; Staples DJ; Sawyer TK; Heinrikson RL; Tomich CS Biochemistry; 1990 Jan; 29(1):264-9. PubMed ID: 2182116 [TBL] [Abstract][Full Text] [Related]
9. In vitro characterization of nonpeptide irreversible inhibitors of HIV proteases. Salto R; Babé LM; Li J; Rosé JR; Yu Z; Burlingame A; De Voss JJ; Sui Z; Ortiz de Montellano P; Craik CS J Biol Chem; 1994 Apr; 269(14):10691-8. PubMed ID: 8144659 [TBL] [Abstract][Full Text] [Related]
10. Antimalarial effects of human immunodeficiency virus type 1 protease inhibitors differ from those of the aspartic protease inhibitor pepstatin. Parikh S; Liu J; Sijwali P; Gut J; Goldberg DE; Rosenthal PJ Antimicrob Agents Chemother; 2006 Jun; 50(6):2207-9. PubMed ID: 16723585 [TBL] [Abstract][Full Text] [Related]
11. Crystallographic analysis of a complex between human immunodeficiency virus type 1 protease and acetyl-pepstatin at 2.0-A resolution. Fitzgerald PM; McKeever BM; VanMiddlesworth JF; Springer JP; Heimbach JC; Leu CT; Herber WK; Dixon RA; Darke PL J Biol Chem; 1990 Aug; 265(24):14209-19. PubMed ID: 2201682 [TBL] [Abstract][Full Text] [Related]
12. Thermodynamics and proton uptake for pepstatin binding to retroviral and eukaryotic aspartic proteases. Xie D; Gulnik S; Collins L; Gustchina E; Bhat TN; Erickson JW Adv Exp Med Biol; 1998; 436():381-6. PubMed ID: 9561245 [No Abstract] [Full Text] [Related]
13. Inhibition of 1,4-beta-D-xylan xylanohydrolase by the specific aspartic protease inhibitor pepstatin: probing the two-step inhibition mechanism. Vathipadiekal V; Rao M J Biol Chem; 2004 Nov; 279(45):47024-33. PubMed ID: 15317808 [TBL] [Abstract][Full Text] [Related]
14. Structural role of the 30's loop in determining the ligand specificity of the human immunodeficiency virus protease. Swairjo MA; Towler EM; Debouck C; Abdel-Meguid SS Biochemistry; 1998 Aug; 37(31):10928-36. PubMed ID: 9692985 [TBL] [Abstract][Full Text] [Related]
15. Trp42 rotamers report reduced flexibility when the inhibitor acetyl-pepstatin is bound to HIV-1 protease. Ullrich B; Laberge M; Tölgyesi F; Szeltner Z; Polgár L; Fidy J Protein Sci; 2000 Nov; 9(11):2232-45. PubMed ID: 11152134 [TBL] [Abstract][Full Text] [Related]
16. Isolation of HIV-1 protease-inhibiting peptides from thermolysin hydrolysate of oyster proteins. Lee TG; Maruyama S Biochem Biophys Res Commun; 1998 Dec; 253(3):604-8. PubMed ID: 9918775 [TBL] [Abstract][Full Text] [Related]
17. Cleavage of the intermediate filament subunit protein vimentin by HIV-1 protease: utilization of a novel cleavage site and identification of higher order polymers of pepstatin A. Shoeman RL; Höner B; Stoller TJ; Mothes E; Kesselmeier C; Traub P; Graves MC Adv Exp Med Biol; 1991; 306():533-7. PubMed ID: 1812754 [No Abstract] [Full Text] [Related]
18. Ionization states of the catalytic residues in HIV-1 protease. Smith R; Brereton IM; Chai RY; Kent SB Nat Struct Biol; 1996 Nov; 3(11):946-50. PubMed ID: 8901873 [TBL] [Abstract][Full Text] [Related]
19. Inhibition of wild-type and mutant human immunodeficiency virus type 1 proteases by GW0385 and other arylsulfonamides. Hanlon MH; Porter DJ; Furfine ES; Spaltenstein A; Carter HL; Danger D; Shu AY; Kaldor IW; Miller JF; Samano VA Biochemistry; 2004 Nov; 43(45):14500-7. PubMed ID: 15533054 [TBL] [Abstract][Full Text] [Related]
20. beta-Galactosidase containing a human immunodeficiency virus protease cleavage site is cleaved and inactivated by human immunodeficiency virus protease. Baum EZ; Bebernitz GA; Gluzman Y Proc Natl Acad Sci U S A; 1990 Dec; 87(24):10023-7. PubMed ID: 2124694 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]